Quality of individual <font color="blue">INR_1</font> control and the risk of <font color="blue">stroke_1</font> <font color="blue">and_1</font> <font color="blue">bleeding_1</font> events in <font color="blue">atrial_1</font> <font color="blue">fibrillation_1</font> patients : a nested case control analysis of the ACTIVE W study . 
<br>
<br> INTRODUCTION <font color="blue">Time_3</font> <font color="blue">in_3</font> <font color="blue">therapeutic_3</font> <font color="blue">range_3</font> <font color="blue">(_3</font> <font color="blue">TTR_3</font> <font color="blue">)_3</font> <font color="blue">for_1</font> <font color="blue">international_2</font> <font color="blue">normalized_2</font> <font color="blue">ratio_2</font> <font color="blue">(_2</font> <font color="blue">INR_2</font> <font color="blue">)_2</font> is an accepted quality measure of <font color="blue">anticoagulation_1</font> control in patient populations , but its usefulness for predicting <font color="blue">stroke_1</font> <font color="blue">and_1</font> <font color="blue">bleeding_1</font> in individuals is not well understood . 
<br> MATERIALS AND METHODS In a nested case control analysis among ACTIVE W study patients , cases with <font color="blue">stroke_1</font> and cases with bleeding were separately matched with controls . <font color="blue">Several_1</font> <font color="blue">anticoagulation_2</font> <font color="blue">quality_1</font> <font color="blue">measures_1</font> were compared , overall and in a time - dependent manner . 
<br> RESULTS 32 cases with <font color="blue">ischemic_1</font> <font color="blue">stroke_1</font> and 234 cases with <font color="blue">bleeding_1</font> in the analysis were matched in a 4:1 ratio to 122 and 865 <font color="blue">controls_1</font> <font color="blue">,_1</font> respectively . Follow - up duration was 257±154days for the <font color="blue">stroke_2</font> <font color="blue">analysis_1</font> and 222±146days for the <font color="blue">bleeding_2</font> <font color="blue">analysis_1</font> <font color="blue">._1</font> Compared with their respective <font color="blue">controls_1</font> <font color="blue">,_1</font> the study mean <font color="blue">TTR_2</font> of both <font color="blue">stroke_2</font> <font color="blue">cases_1</font> <font color="blue">(_1</font> <font color="blue">53.9%±25.1_1</font> <font color="blue">vs_1</font> <font color="blue">63.4%±24.8_1</font> <font color="blue">;_1</font> <font color="blue">p=0.055_1</font> <font color="blue">)_1</font> and <font color="blue">bleeding_1</font> <font color="blue">cases_1</font> <font color="blue">(_1</font> <font color="blue">56.2%±25.4_1</font> <font color="blue">vs_1</font> <font color="blue">63.4%±26.8_1</font> <font color="blue">;_1</font> <font color="blue">p<0.001_1</font> <font color="blue">)_1</font> <font color="blue">was_1</font> lower . Time below range for <font color="blue">stroke_2</font> and time above range for <font color="blue">bleeding_1</font> were only greater in the last month leading up to the event , not over the entire study period . Rather , over the entire study period <font color="blue">bleeding_2</font> <font color="blue">cases_1</font> spent more time below range than <font color="blue">controls_1</font> <font color="blue">(_1</font> <font color="blue">26.8%±25.9_1</font> <font color="blue">vs_1</font> <font color="blue">20.8%±24.0_1</font> <font color="blue">;_1</font> <font color="blue">p=0.001_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> 
<br> CONCLUSIONS <font color="blue">TTR_2</font> was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W. Maintaining a high <font color="blue">TTR_2</font> <font color="blue">,_2</font> with equal importance to avoid low and high <font color="blue">INRs_1</font> <font color="blue">,_1</font> is a relevant goal of individual patient treatment to prevent <font color="blue">stroke_1</font> <font color="blue">and_1</font> <font color="blue">bleeding_1</font> <font color="blue">._1</font>